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Glycosidase inhibitors are enjoying much interest, as they are
finding applications in the treatment of diabetes and influenza and
as chemical chaperones in lysosomal storage disorders.1 Iminoaldi-
tols rank among the most powerful glycosidase inhibitors and have
accordingly been the topic of extensive study.2,3 Two major classes
of six-membered-ring iminoalditols are the nojirimycin class,4 in
which the endocyclic ring oxygen of a pyranose is replaced by
nitrogen, and the noeuromycin class,5 in which the anomeric center
is replaced by nitrogen and the endocyclic oxygen by a methylene
unit. The reliable potency of these inhibitors toward glycoside
hydrolases derives from beneficial charge-charge interactions with
conserved enzymatic residues found at the active center. Their
potency is often attributed to mimicry of electrostatic features of
the oxocarbenium ion-like transition states proposed for most
glycosidases.6,7 Five-membered-ring iminoalditols have also been
found to be potent inhibitors of glycoside furanosidases8 and
nucleoside hydrolases.9 Interestingly, such five-membered-ring
iminoalditols have also been found to potently inhibit a wide range
of glycoside pyranosidases.2,10-14
More recently, unnatural seven-membered-ring iminoalditols
(perhaps more appropriately referred to as azepanes) have been
found to inhibit glycosidases.15 This observation has invigorated
efforts directed toward their efficient synthesis and probing of their
biological activities.15-20 Although recent efforts have highlighted
the basis for the binding of five-membered-ring iminoalditols to
glycosidases,14 the molecular details mediating binding by azepanes
to glycosidases remains unknown.
One glycosidase hydrolase that has generated recent interest is
the cytoplasmic -N-acetylglucosaminidase (O-GlcNAcase)21 that
processes nucleocytoplasmic proteins post-translationally modified
with 2-acetamido-2-deoxy-D-glucopyranose residues [Figure 1,
GlcNAc (1)] -O-linked to serine or threonine residues (O-
GlcNAc).22 This family 84 glycoside hydrolase (GH84) plays a
role in multiple cellular processes.23 Its catalytic mechanism has
been shown to involve anchimeric assistance from the acetamido
group of the substrate.24 Notably, the structure of a -N-acetyl-
glucosaminidase from Bacteroides thetaiotaomicron (BtGH84) has
revealed an active site in which all but one amino acid residue is
conserved with respect to that of human O-GlcNAcase,25 which
makes BtGH84, along with the Clostridial GH84 enzyme,26 valuable
models for studying inhibition of O-GlcNAcase.27,28 Human
O-GlcNAcase inhibitors offer insights into the biological roles of
O-GlcNAc without suffering the loss of protein-protein interactions
that may complicate interpretation of gene knockouts and knock-
downs.29
Motivated by interest in the function of this enzyme and the need
for useful inhibitors, coupled with the lack of understanding of the
molecular basis upon which azepanes inhibit glycosidases more
generally,15,30 we undertook detailed studies of the inhibition of
O-GlcNAcase by several new azepanes. Here we report the
synthesis of new azepanes such as 4 and 5, which, unlike their
six-membered-ring counterparts that bear relatively unstable hemi-
aminal (Figure 1, 2)31 or gem-diamine (Figure 1, 3)32 functionalities,
should be chemically stable in biological media by virtue of the
inserted methylene unit (Figure 1, 4 and 5). We then investigate
the potency of these inhibitors toward GH84 enzymes, including
human O-GlcNAcase, and evaluate the detailed molecular basis
for their potency using X-ray structural studies and molecular
simulations.
As a first step, we synthesized azepanes 4 and 5, since these
molecules are analogous to the nojirimycin and noeuromycin classes
of inhibitors, respectively, except that a methylene unit is inserted
adjacent to the endocyclic nitrogen. Otherwise, both molecules have
a relative stereochemical disposition of substituents that mimics
that of the natural D-gluco-configured substrates. We therefore
anticipated that these molecules would inhibit O-GlcNAcase. These
two targets of interest were conveniently obtained from known
azepanes33,34 using two concise routes (Supplemental Scheme 1
in the Supporting Information).
To generate additional molecules that would allow us to verify
or reject our hypothesis that the relative configuration of substituents
is essential for potent inhibition of O-GlcNAcase, we prepared
several conveniently accessible diastereomers having incorrect
configurations. Azepanes 6, 7, and 8, displaying R-D-manno-, R-L-
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Figure 1. Structures of GlcNAc (1), nojirimycin-like 2, noeuromycin-like
3, -D-gluco-like configured target azepane 4, target azepane 5, diastere-
omers of the target azepanes with R-D-manno- (6), R-L-ido- (7), and -L-
gulo-like (8) configurations, and PUGNAc (9).
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ido- and -L-gulo-like configurations respectively, were obtained
from the corresponding seven-membered-ring azido alcohols.33 We
expected compounds 6-8 to be poor inhibitors of O-GlcNAcase
because of the absence of the sequential trans relationship of the
substituents seen in azepanes 4 and 5 as well as in the nojirimycin
(2) and noeuromycin (3) classes of inhibitors.
With azepanes 4-8 in hand, we evaluated their inhibitory
properties against both human O-GlcNAcase and BtGH84 (Table
1). As we anticipated, azepanes 4 and 5 are potent competitive
inhibitors [see Supplemental Figure (SF) 3], suggesting that these
molecules adopt a conformation within the enzyme active site that
places these groups in positions that mimic those of the substrate.
Support for this view is gained from the observation that azepanes
6-8 are poor inhibitors of these GH84 enzymes, likely because of
the inappropriate configuration of substituents. Azepanes 4 and 5
therefore bind some 30- and 140-fold more tightly than the product
(GlcNAc, 1, Ki ) 1500 µM,24 Figure 1) of the O-GlcNAcase-
catalyzed reaction itself.
In order to gain insight into the molecular basis of inhibition of
O-GlcNAcase, crystals of BtGH84 were soaked in solutions
containing azepanes 4-8. In keeping with their respective Ki values,
ordered binding to the enzyme was only observed for 4 and 5. These
3D structures, determined to ∼2.3 Å resolution, reveal clear,
conformationally unambiguous electron density for both 4 and 5
bound in the active site of BtGH84 (Figure 2). These 3D structures
elegantly offer a molecular rationale for the stereochemical require-
ments for binding to GH84 enzymes. As we had anticipated, the
enzyme-bound dispositions of the substituents of compounds 4 and
5 closely match those of the glucopyranose-configured inhibitors
of GH84 enzymes such as PUGNAc (9)21,35 (Figure 1). Conversely,
compounds 6-8, which display configurations equating to R-D-
manno, R-L-ido and -L-gulo configurations, have incorrect stere-
ochemistry at centers C5/C6 (6), C2 (7), and C2/C5/C6 (8),
respectively (see 4 in Figure 1 for numbering).
Briefly, this configurationally selective binding is promoted by
hydrogen bonding of the hydroxymethyl group and O3 to Asp344
and of O3 to Asn372, with O4 receiving a hydrogen bond from Lys166
while donating one to the main-chain carbonyl of Gly135 (Figure
3). At the reaction center, the amide nitrogen forms a hydrogen
bond with catalytic residue Asp242. Most notably, we also observe
an unusual conformation for the ring of azepane 4 in which both
the acetamido group and the pseudoanomeric hydroxyl groups are
oriented transdiaxially. This conformation is likely made possible
by favorable interactions of these two substituents with the
conserved residues Asp242 and the acid/base Asp243 (Figures 2 and
3). This arrangement, in which the “anomeric” hydroxyl group
hydrogen-bonds to the general acid is reminiscent of the rather rarely
observed enzyme-substrate complexes in which the general acid
H-bonds to the glycosidic oxygen.6 Azepane 5 adopts a conforma-
tion placing the “pseudoanomeric” carbon (C2) in the same position
as that observed for C6 of azepane 4, despite the lack of the
“anomeric” hydroxyl group. It is also notable that consistent with
the requirements for neighboring-group participation in catalysis,
this transaxial arrangement places the N-acetyl carbonyl group 3.4
Å from the “anomeric” center with, in the case of 4, a
CdO · · ·C6 · · ·O6 angle of ∼150°, corresponding to an appropriate
geometry for in-line nucleophilic substitution at the anomeric
carbon. Correct attack orientation for the carbonyl is likely also
enhanced by the hydrogen bond to Asn339.
Given the unusual conformation of these azepanes bound to
BtGH84 and the considerable conformational flexibility of these
molecules, we aimed to ascertain whether these inhibitors adopt a
conformation in solution that might resemble the one observed
within the enzyme active site or, more likely, whether they adopt
a different conformation that may then either be “selected” from
solution or, alternatively, bind and then “mold” to the active site
to optimize the interactions. To gain insight into this question, we
examined the NMR data and carried out molecular mechanics (MM)
and molecular dynamics (MD) simulations. For azepane 4, the
observed vicinal coupling constants (J5,6 ) 6.5 Hz; J4,5 ) 8.6 Hz;
J3,4 ) 8.6 Hz; J2,3 ) 7.3 Hz; J2,8a ) 3.5 Hz; J2,8b ) 9.3 Hz; J6,7a )
2.7 Hz; J6,7b ) 6.5 Hz) resemble those experimentally observed by
Peczuh and co-workers36 for methyl R-D-glycero-D-idoseptanoside
Table 1. Inhibition Constants (Ki) for the Inhibitors and Enzymes
Studieda
Ki (µM)
inhibitor O-GlcNAcase BtGH84
GlcNAc (1)b 1500c not determined
PUGNAc (9) 0.046c,d 0.010e
4 51 ( 5 89 ( 3
5 11 ( 1 8 ( 1
6 280 ( 40 >1000
7 480 ( 90 490 ( 130
8 1600 660 ( 50
a Assays for human O-GlcNAcase were carried out at 37 °C using
p-nitrophenyl-2-acetamido-2-deoxy--D-glucopyranoside (pNP-GlcNAc)
as the substrate in 50 mM NaPi, 100 mM NaCl (pH 7.4). For BtGH84,
assays were carried out at 25 °C using pNP-GlcNAc as the substrate in
50 mM MES, 200 mM NaCl (pH 6.5). See the Supporting Information
for further details. b Product of the O-GlcNAcase-catalyzed reaction.
c Reference 24. d Reference 21. e Reference 25.
Figure 2. Observed electron density (2Fobs - Fcalc at 1σ) for azepanes 4
and 5 bound to BtGH84 and major conformations of 4 and 5 in solution.
(a) Mono “side-on” view of 4. (b) Mono “front-on” view of 4, with some
residues mentioned in the text shown in ball-and-stick representation. (c)
Major conformer of 4 as established by MM (green) overlaid with the bound
structure (gray). (d-f) Same as (a-c) but with 5 rather than 4.
Figure 3. Representation of close (<3.1 Å) contacts of 4 with BtGH84.
(10) (see SF 2). Compound 10 has been described as adopting
primarily a 3,4TC5,6 conformation in solution, with substituents at
positions 1, 2, 3, 4, and 5 in equatorial-like orientations (numbering
as in SF 2). The relatively small values we observe for J5,6 and J2,3
of 4, however, indicate that other minor conformers are also present
and details of experimental protocols. This material is available free
of charge via the Internet at http://pubs.acs.org.
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in solution. MM3* calculations also indicate that other conforma-
tions are present (see SF 4), although the contribution of the 4,5TC2,3 
conformer likely is greater than 80%. On the basis of these results 
(Figure 2c), the predominant conformers in solution do not match 
that of the enzyme-bound inhibitor, and therefore, the enzyme either 
selects for a minor solution conformer or optimizes the conformation 
of the inhibitor within the active site.
For azepane 5, the experimental couplings (J2a,3 ) 2.4 Hz; J2b,3
) 6.6 Hz; J3,4 ) 6.6 Hz; J4,5 ) 6.6 Hz; J5,6 ) 9.7 Hz; J6,7a ) 9.7 
Hz; J6,7b ) 2.7 Hz) also suggest one major conformation, especially 
around the region defined by couplings between H5 and H6 and 
H6 and H7a,b, which, in view of the magnitude of the couplings, 
likely have an antitype relationship. The value of 6.6 Hz for J3,4
and J4,5, however, suggests that conformers having different torsion 
angles in this region also contribute. MD simulations using the 
MM3* force field offer more precise insight into the actual 
conformational equilibrium: an almost 1:1 ratio between the 4,5CN,2 
and 5,6T2,3 conformers is consistent with the experimental coupling 
constants (see SF 5).36 Here, too, it is clear that the conformation 
in solution differs significantly from that seen when the inhibitor 
is bound to BtGH84 (Figure 2f).
The use of chemically stable but conformationally flexible 
polyhydroxylated azepanes thus allows the ring to adopt alternate 
conformations within the enzyme active site. These conformations 
offer insight into the preferred distorted conformation of bound 
substrates. The 1,2 transdiaxial arrangement of the pseudoanomeric 
-hydroxyl and acetamido groups in azepane 4 occurs by virtue of 
its adoption of a NC4,5 chair conformation, whereas 5 adopts a 
slightly distorted 2B5,6 conformation (Figures 2 and 3). These seven-
membered-ring conformations, both of which place the “anomeric” 
carbon above the ring, are analogous to the 4E and 1,4Bboat con-
formations adopted by the relatively rarely observed Michaelis 
complexes of GlcNAc-hydrolyzing enzymes, including mutant 
chitinases37 and -N-acetylglucosaminidases,38 and are further 
supported by the strong inhibition of these enzymes by polyhy-
droxylated isoquinuclidines.39
In summary, complexation of these azepane inhibitors with a 
glycoside hydrolase reveals the detailed basis for inhibition by this 
growing class of compounds. The structures of these GH84 
complexes further suggest how substrates may bind and thereby 
enable hydrolysis with retention of anomeric configuration through 
neighboring-group participation. The conformational flexibility of 
the azepane class of inhibitors therefore may offer a generally useful 
approach for continued study of glycosidase conformational 
pathways.
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